The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global SWFI for Reconstitution of Lyophilized Drugs Market Research Report 2025
Synopsis
Sterile Water for Injection (SWFI) is sterile, nonpyrogenic, distilled water in a single dose container for intravenous administration after addition of a suitable solute. It may also be used as a dispensing container for diluent use.
SWFI are used for reconstitution of lyophilized drugs, diluent of injection solution and rinsing agent for endoscopy in various departments. SWFI for reconstitution of lyophilized drugs.
In this report, we only collect data of SWFI being sold as a part of set with LYO drug.
The global SWFI for Reconstitution of Lyophilized Drugs market was valued at US$ 13 million in 2023 and is anticipated to reach US$ 19 million by 2030, witnessing a CAGR of 5.4% during the forecast period 2024-2030.
Asia-Pacific and Europe are the two largest consumption regions, with a consumption market share nearly 40% and 30%. North America is also an important sales region.
Market competition is intense. Baxter, Hospira (ICU Medical), Vetter, Otsuka, ROVI, Fresenius Kabi, etc. are the leaders of the industry, they hold key technologies and patents, with high-end customers.
The classification of SWFI for reconstitution of lyophilized drugs includes Vials and Ampoules and Pre-Filled Syringes. The sales proportion of Vials and Ampoules is over 95%.
SWFI for reconstitution of lyophilized drugs is widely used for vaccines, Biological Products, Bio-pharmaceutical. The most proportion of SWFI for reconstitution of lyophilized drugs is used for vaccine, the proportion is about 73%.
This report aims to provide a comprehensive presentation of the global market for SWFI for Reconstitution of Lyophilized Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding SWFI for Reconstitution of Lyophilized Drugs.
Report Scope
The SWFI for Reconstitution of Lyophilized Drugs market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global SWFI for Reconstitution of Lyophilized Drugs market comprehensively. Regional market sizes, concerning products by Container, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the SWFI for Reconstitution of Lyophilized Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Container, by Application, and by regions.
Market Segmentation
By Company
Baxter
Hospira (ICU Medical)
Vetter
Otsuka
ROVI
Fresenius Kabi
Shijiazhuang No. 4 Pharmaceutical
Hikma
Kelun
Deo Gratias Parenteral
Segment by Container
Vials and Ampoules
Pre-Filled Syringes
Segment by Application
Vaccine
Biological Products
Bio-Pharmaceutical
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Container, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of SWFI for Reconstitution of Lyophilized Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of SWFI for Reconstitution of Lyophilized Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Container, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Sterile Water for Injection (SWFI) is sterile, nonpyrogenic, distilled water in a single dose container for intravenous administration after addition of a suitable solute. It may also be used as a dispensing container for diluent use.
SWFI are used for reconstitution of lyophilized drugs, diluent of injection solution and rinsing agent for endoscopy in various departments. SWFI for reconstitution of lyophilized drugs.
In this report, we only collect data of SWFI being sold as a part of set with LYO drug.
The global SWFI for Reconstitution of Lyophilized Drugs market was valued at US$ 13 million in 2023 and is anticipated to reach US$ 19 million by 2030, witnessing a CAGR of 5.4% during the forecast period 2024-2030.
Asia-Pacific and Europe are the two largest consumption regions, with a consumption market share nearly 40% and 30%. North America is also an important sales region.
Market competition is intense. Baxter, Hospira (ICU Medical), Vetter, Otsuka, ROVI, Fresenius Kabi, etc. are the leaders of the industry, they hold key technologies and patents, with high-end customers.
The classification of SWFI for reconstitution of lyophilized drugs includes Vials and Ampoules and Pre-Filled Syringes. The sales proportion of Vials and Ampoules is over 95%.
SWFI for reconstitution of lyophilized drugs is widely used for vaccines, Biological Products, Bio-pharmaceutical. The most proportion of SWFI for reconstitution of lyophilized drugs is used for vaccine, the proportion is about 73%.
This report aims to provide a comprehensive presentation of the global market for SWFI for Reconstitution of Lyophilized Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding SWFI for Reconstitution of Lyophilized Drugs.
Report Scope
The SWFI for Reconstitution of Lyophilized Drugs market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global SWFI for Reconstitution of Lyophilized Drugs market comprehensively. Regional market sizes, concerning products by Container, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the SWFI for Reconstitution of Lyophilized Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Container, by Application, and by regions.
Market Segmentation
By Company
Baxter
Hospira (ICU Medical)
Vetter
Otsuka
ROVI
Fresenius Kabi
Shijiazhuang No. 4 Pharmaceutical
Hikma
Kelun
Deo Gratias Parenteral
Segment by Container
Vials and Ampoules
Pre-Filled Syringes
Segment by Application
Vaccine
Biological Products
Bio-Pharmaceutical
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Container, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of SWFI for Reconstitution of Lyophilized Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of SWFI for Reconstitution of Lyophilized Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Container, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 SWFI for Reconstitution of Lyophilized Drugs Market Overview
1.1 Product Overview and Scope of SWFI for Reconstitution of Lyophilized Drugs
1.2 SWFI for Reconstitution of Lyophilized Drugs Segment by Container
1.2.1 Global SWFI for Reconstitution of Lyophilized Drugs Market Value Comparison by Container (2024-2030)
1.2.2 Vials and Ampoules
1.2.3 Pre-Filled Syringes
1.3 SWFI for Reconstitution of Lyophilized Drugs Segment by Application
1.3.1 Global SWFI for Reconstitution of Lyophilized Drugs Market Value by Application: (2024-2030)
1.3.2 Vaccine
1.3.3 Biological Products
1.3.4 Bio-Pharmaceutical
1.4 Global SWFI for Reconstitution of Lyophilized Drugs Market Size Estimates and Forecasts
1.4.1 Global SWFI for Reconstitution of Lyophilized Drugs Revenue 2019-2030
1.4.2 Global SWFI for Reconstitution of Lyophilized Drugs Sales 2019-2030
1.4.3 Global SWFI for Reconstitution of Lyophilized Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 SWFI for Reconstitution of Lyophilized Drugs Market Competition by Manufacturers
2.1 Global SWFI for Reconstitution of Lyophilized Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global SWFI for Reconstitution of Lyophilized Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global SWFI for Reconstitution of Lyophilized Drugs Average Price by Manufacturers (2019-2024)
2.4 Global SWFI for Reconstitution of Lyophilized Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of SWFI for Reconstitution of Lyophilized Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of SWFI for Reconstitution of Lyophilized Drugs, Product Type & Application
2.7 SWFI for Reconstitution of Lyophilized Drugs Market Competitive Situation and Trends
2.7.1 SWFI for Reconstitution of Lyophilized Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest SWFI for Reconstitution of Lyophilized Drugs Players Market Share by Revenue
2.7.3 Global SWFI for Reconstitution of Lyophilized Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 SWFI for Reconstitution of Lyophilized Drugs Retrospective Market Scenario by Region
3.1 Global SWFI for Reconstitution of Lyophilized Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global SWFI for Reconstitution of Lyophilized Drugs Global SWFI for Reconstitution of Lyophilized Drugs Sales by Region: 2019-2030
3.2.1 Global SWFI for Reconstitution of Lyophilized Drugs Sales by Region: 2019-2024
3.2.2 Global SWFI for Reconstitution of Lyophilized Drugs Sales by Region: 2025-2030
3.3 Global SWFI for Reconstitution of Lyophilized Drugs Global SWFI for Reconstitution of Lyophilized Drugs Revenue by Region: 2019-2030
3.3.1 Global SWFI for Reconstitution of Lyophilized Drugs Revenue by Region: 2019-2024
3.3.2 Global SWFI for Reconstitution of Lyophilized Drugs Revenue by Region: 2025-2030
3.4 North America SWFI for Reconstitution of Lyophilized Drugs Market Facts & Figures by Country
3.4.1 North America SWFI for Reconstitution of Lyophilized Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America SWFI for Reconstitution of Lyophilized Drugs Sales by Country (2019-2030)
3.4.3 North America SWFI for Reconstitution of Lyophilized Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe SWFI for Reconstitution of Lyophilized Drugs Market Facts & Figures by Country
3.5.1 Europe SWFI for Reconstitution of Lyophilized Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe SWFI for Reconstitution of Lyophilized Drugs Sales by Country (2019-2030)
3.5.3 Europe SWFI for Reconstitution of Lyophilized Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific SWFI for Reconstitution of Lyophilized Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific SWFI for Reconstitution of Lyophilized Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific SWFI for Reconstitution of Lyophilized Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific SWFI for Reconstitution of Lyophilized Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America SWFI for Reconstitution of Lyophilized Drugs Market Facts & Figures by Country
3.7.1 Latin America SWFI for Reconstitution of Lyophilized Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America SWFI for Reconstitution of Lyophilized Drugs Sales by Country (2019-2030)
3.7.3 Latin America SWFI for Reconstitution of Lyophilized Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa SWFI for Reconstitution of Lyophilized Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa SWFI for Reconstitution of Lyophilized Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa SWFI for Reconstitution of Lyophilized Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa SWFI for Reconstitution of Lyophilized Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Container
4.1 Global SWFI for Reconstitution of Lyophilized Drugs Sales by Container (2019-2030)
4.1.1 Global SWFI for Reconstitution of Lyophilized Drugs Sales by Container (2019-2024)
4.1.2 Global SWFI for Reconstitution of Lyophilized Drugs Sales by Container (2025-2030)
4.1.3 Global SWFI for Reconstitution of Lyophilized Drugs Sales Market Share by Container (2019-2030)
4.2 Global SWFI for Reconstitution of Lyophilized Drugs Revenue by Container (2019-2030)
4.2.1 Global SWFI for Reconstitution of Lyophilized Drugs Revenue by Container (2019-2024)
4.2.2 Global SWFI for Reconstitution of Lyophilized Drugs Revenue by Container (2025-2030)
4.2.3 Global SWFI for Reconstitution of Lyophilized Drugs Revenue Market Share by Container (2019-2030)
4.3 Global SWFI for Reconstitution of Lyophilized Drugs Price by Container (2019-2030)
5 Segment by Application
5.1 Global SWFI for Reconstitution of Lyophilized Drugs Sales by Application (2019-2030)
5.1.1 Global SWFI for Reconstitution of Lyophilized Drugs Sales by Application (2019-2024)
5.1.2 Global SWFI for Reconstitution of Lyophilized Drugs Sales by Application (2025-2030)
5.1.3 Global SWFI for Reconstitution of Lyophilized Drugs Sales Market Share by Application (2019-2030)
5.2 Global SWFI for Reconstitution of Lyophilized Drugs Revenue by Application (2019-2030)
5.2.1 Global SWFI for Reconstitution of Lyophilized Drugs Revenue by Application (2019-2024)
5.2.2 Global SWFI for Reconstitution of Lyophilized Drugs Revenue by Application (2025-2030)
5.2.3 Global SWFI for Reconstitution of Lyophilized Drugs Revenue Market Share by Application (2019-2030)
5.3 Global SWFI for Reconstitution of Lyophilized Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Baxter
6.1.1 Baxter Corporation Information
6.1.2 Baxter Description and Business Overview
6.1.3 Baxter SWFI for Reconstitution of Lyophilized Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Baxter SWFI for Reconstitution of Lyophilized Drugs Product Portfolio
6.1.5 Baxter Recent Developments/Updates
6.2 Hospira (ICU Medical)
6.2.1 Hospira (ICU Medical) Corporation Information
6.2.2 Hospira (ICU Medical) Description and Business Overview
6.2.3 Hospira (ICU Medical) SWFI for Reconstitution of Lyophilized Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Hospira (ICU Medical) SWFI for Reconstitution of Lyophilized Drugs Product Portfolio
6.2.5 Hospira (ICU Medical) Recent Developments/Updates
6.3 Vetter
6.3.1 Vetter Corporation Information
6.3.2 Vetter Description and Business Overview
6.3.3 Vetter SWFI for Reconstitution of Lyophilized Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Vetter SWFI for Reconstitution of Lyophilized Drugs Product Portfolio
6.3.5 Vetter Recent Developments/Updates
6.4 Otsuka
6.4.1 Otsuka Corporation Information
6.4.2 Otsuka Description and Business Overview
6.4.3 Otsuka SWFI for Reconstitution of Lyophilized Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Otsuka SWFI for Reconstitution of Lyophilized Drugs Product Portfolio
6.4.5 Otsuka Recent Developments/Updates
6.5 ROVI
6.5.1 ROVI Corporation Information
6.5.2 ROVI Description and Business Overview
6.5.3 ROVI SWFI for Reconstitution of Lyophilized Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 ROVI SWFI for Reconstitution of Lyophilized Drugs Product Portfolio
6.5.5 ROVI Recent Developments/Updates
6.6 Fresenius Kabi
6.6.1 Fresenius Kabi Corporation Information
6.6.2 Fresenius Kabi Description and Business Overview
6.6.3 Fresenius Kabi SWFI for Reconstitution of Lyophilized Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Fresenius Kabi SWFI for Reconstitution of Lyophilized Drugs Product Portfolio
6.6.5 Fresenius Kabi Recent Developments/Updates
6.7 Shijiazhuang No. 4 Pharmaceutical
6.6.1 Shijiazhuang No. 4 Pharmaceutical Corporation Information
6.6.2 Shijiazhuang No. 4 Pharmaceutical Description and Business Overview
6.6.3 Shijiazhuang No. 4 Pharmaceutical SWFI for Reconstitution of Lyophilized Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Shijiazhuang No. 4 Pharmaceutical SWFI for Reconstitution of Lyophilized Drugs Product Portfolio
6.7.5 Shijiazhuang No. 4 Pharmaceutical Recent Developments/Updates
6.8 Hikma
6.8.1 Hikma Corporation Information
6.8.2 Hikma Description and Business Overview
6.8.3 Hikma SWFI for Reconstitution of Lyophilized Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hikma SWFI for Reconstitution of Lyophilized Drugs Product Portfolio
6.8.5 Hikma Recent Developments/Updates
6.9 Kelun
6.9.1 Kelun Corporation Information
6.9.2 Kelun Description and Business Overview
6.9.3 Kelun SWFI for Reconstitution of Lyophilized Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Kelun SWFI for Reconstitution of Lyophilized Drugs Product Portfolio
6.9.5 Kelun Recent Developments/Updates
6.10 Deo Gratias Parenteral
6.10.1 Deo Gratias Parenteral Corporation Information
6.10.2 Deo Gratias Parenteral Description and Business Overview
6.10.3 Deo Gratias Parenteral SWFI for Reconstitution of Lyophilized Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Deo Gratias Parenteral SWFI for Reconstitution of Lyophilized Drugs Product Portfolio
6.10.5 Deo Gratias Parenteral Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 SWFI for Reconstitution of Lyophilized Drugs Industry Chain Analysis
7.2 SWFI for Reconstitution of Lyophilized Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 SWFI for Reconstitution of Lyophilized Drugs Production Mode & Process
7.4 SWFI for Reconstitution of Lyophilized Drugs Sales and Marketing
7.4.1 SWFI for Reconstitution of Lyophilized Drugs Sales Channels
7.4.2 SWFI for Reconstitution of Lyophilized Drugs Distributors
7.5 SWFI for Reconstitution of Lyophilized Drugs Customers
8 SWFI for Reconstitution of Lyophilized Drugs Market Dynamics
8.1 SWFI for Reconstitution of Lyophilized Drugs Industry Trends
8.2 SWFI for Reconstitution of Lyophilized Drugs Market Drivers
8.3 SWFI for Reconstitution of Lyophilized Drugs Market Challenges
8.4 SWFI for Reconstitution of Lyophilized Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
